These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
176 related articles for article (PubMed ID: 31981476)
1. A Toxic RNA Catalyzes the Cellular Synthesis of Its Own Inhibitor, Shunting It to Endogenous Decay Pathways. Benhamou RI; Angelbello AJ; Wang ET; Disney MD Cell Chem Biol; 2020 Feb; 27(2):223-231.e4. PubMed ID: 31981476 [TBL] [Abstract][Full Text] [Related]
2. A Druglike Small Molecule that Targets r(CCUG) Repeats in Myotonic Dystrophy Type 2 Facilitates Degradation by RNA Quality Control Pathways. Wagner-Griffin S; Abe M; Benhamou RI; Angelbello AJ; Vishnu K; Chen JL; Childs-Disney JL; Disney MD J Med Chem; 2021 Jun; 64(12):8474-8485. PubMed ID: 34101465 [TBL] [Abstract][Full Text] [Related]
3. Structure-Specific Cleavage of an RNA Repeat Expansion with a Dimeric Small Molecule Is Advantageous over Sequence-Specific Recognition by an Oligonucleotide. Benhamou RI; Angelbello AJ; Andrews RJ; Wang ET; Moss WN; Disney MD ACS Chem Biol; 2020 Feb; 15(2):485-493. PubMed ID: 31927948 [TBL] [Abstract][Full Text] [Related]
4. Induction and reversal of myotonic dystrophy type 1 pre-mRNA splicing defects by small molecules. Childs-Disney JL; Stepniak-Konieczna E; Tran T; Yildirim I; Park H; Chen CZ; Hoskins J; Southall N; Marugan JJ; Patnaik S; Zheng W; Austin CP; Schatz GC; Sobczak K; Thornton CA; Disney MD Nat Commun; 2013; 4():2044. PubMed ID: 23806903 [TBL] [Abstract][Full Text] [Related]
5. Pseudouridine Modification Inhibits Muscleblind-like 1 (MBNL1) Binding to CCUG Repeats and Minimally Structured RNA through Reduced RNA Flexibility. deLorimier E; Hinman MN; Copperman J; Datta K; Guenza M; Berglund JA J Biol Chem; 2017 Mar; 292(10):4350-4357. PubMed ID: 28130447 [TBL] [Abstract][Full Text] [Related]
6. A flow cytometry-based screen identifies MBNL1 modulators that rescue splicing defects in myotonic dystrophy type I. Zhang F; Bodycombe NE; Haskell KM; Sun YL; Wang ET; Morris CA; Jones LH; Wood LD; Pletcher MT Hum Mol Genet; 2017 Aug; 26(16):3056-3068. PubMed ID: 28535287 [TBL] [Abstract][Full Text] [Related]
7. Rationally designed small molecules targeting the RNA that causes myotonic dystrophy type 1 are potently bioactive. Childs-Disney JL; Hoskins J; Rzuczek SG; Thornton CA; Disney MD ACS Chem Biol; 2012 May; 7(5):856-62. PubMed ID: 22332923 [TBL] [Abstract][Full Text] [Related]
8. Development of pharmacophore models for small molecules targeting RNA: Application to the RNA repeat expansion in myotonic dystrophy type 1. Angelbello AJ; González ÀL; Rzuczek SG; Disney MD Bioorg Med Chem Lett; 2016 Dec; 26(23):5792-5796. PubMed ID: 27839685 [TBL] [Abstract][Full Text] [Related]
9. (CCUG) Yenigun VB; Sirito M; Amcheslavky A; Czernuszewicz T; Colonques-Bellmunt J; García-Alcover I; Wojciechowska M; Bolduc C; Chen Z; López Castel A; Krahe R; Bergmann A Dis Model Mech; 2017 Aug; 10(8):993-1003. PubMed ID: 28623239 [TBL] [Abstract][Full Text] [Related]
10. Small molecules that target the toxic RNA in myotonic dystrophy type 2. Nguyen L; Lee J; Wong CH; Zimmerman SC ChemMedChem; 2014 Nov; 9(11):2455-62. PubMed ID: 24938413 [TBL] [Abstract][Full Text] [Related]
11. Short Tandem Repeat Expansions and RNA-Mediated Pathogenesis in Myotonic Dystrophy. Sznajder ŁJ; Swanson MS Int J Mol Sci; 2019 Jul; 20(13):. PubMed ID: 31323950 [TBL] [Abstract][Full Text] [Related]
13. CCUG repeats reduce the rate of global protein synthesis in myotonic dystrophy type 2. Schneider-Gold C; Timchenko LT Rev Neurosci; 2010; 21(1):19-28. PubMed ID: 20458885 [TBL] [Abstract][Full Text] [Related]
14. Ribonuclear inclusions and MBNL1 nuclear sequestration do not affect myoblast differentiation but alter gene splicing in myotonic dystrophy type 2. Cardani R; Baldassa S; Botta A; Rinaldi F; Novelli G; Mancinelli E; Meola G Neuromuscul Disord; 2009 May; 19(5):335-43. PubMed ID: 19345584 [TBL] [Abstract][Full Text] [Related]
15. Muscleblind-like protein 1 nuclear sequestration is a molecular pathology marker of DM1 and DM2. Cardani R; Mancinelli E; Rotondo G; Sansone V; Meola G Eur J Histochem; 2006; 50(3):177-82. PubMed ID: 16920640 [TBL] [Abstract][Full Text] [Related]
16. Chemical correction of pre-mRNA splicing defects associated with sequestration of muscleblind-like 1 protein by expanded r(CAG)-containing transcripts. Kumar A; Parkesh R; Sznajder LJ; Childs-Disney JL; Sobczak K; Disney MD ACS Chem Biol; 2012 Mar; 7(3):496-505. PubMed ID: 22252896 [TBL] [Abstract][Full Text] [Related]
17. A fly model for the CCUG-repeat expansion of myotonic dystrophy type 2 reveals a novel interaction with MBNL1. Yu Z; Goodman LD; Shieh SY; Min M; Teng X; Zhu Y; Bonini NM Hum Mol Genet; 2015 Feb; 24(4):954-62. PubMed ID: 25305073 [TBL] [Abstract][Full Text] [Related]
18. Selective inhibition of MBNL1-CCUG interaction by small molecules toward potential therapeutic agents for myotonic dystrophy type 2 (DM2). Wong CH; Fu Y; Ramisetty SR; Baranger AM; Zimmerman SC Nucleic Acids Res; 2011 Nov; 39(20):8881-90. PubMed ID: 21768123 [TBL] [Abstract][Full Text] [Related]
19. Muscleblind protein, MBNL1/EXP, binds specifically to CHHG repeats. Kino Y; Mori D; Oma Y; Takeshita Y; Sasagawa N; Ishiura S Hum Mol Genet; 2004 Mar; 13(5):495-507. PubMed ID: 14722159 [TBL] [Abstract][Full Text] [Related]
20. RNA/MBNL1-containing foci in myoblast nuclei from patients affected by myotonic dystrophy type 2: an immunocytochemical study. Perdoni F; Malatesta M; Cardani R; Giagnacovo M; Mancinelli E; Meola G; Pellicciari C Eur J Histochem; 2009 Sep; 53(3):e18. PubMed ID: 19864209 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]